TANG CAPITAL MANAGEMENT LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001232621
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 127 positions · Total reported value $937.87M · Top-10 concentration 36.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 15.2% · 5 new · 1 cut · 1 exited
Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -8.5% · vs SPY -10.6% · Prev Value $2.20B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -3.0% · vs SPY -5.2% · Latest Value $2.17B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, TANG CAPITAL MANAGEMENT LLC disclosed 127 equity positions with a combined reported value of $937.87M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 36.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt.
The largest disclosed positions as of Q2 2024 were TARS ($61.29M), EOLS ($52.59M), KALV ($49.70M). By sector, the heaviest allocations are Health Care 76.8%, Technology 2.2%. Versus the prior quarter, allocation shifted toward Technology (+0.8pp), Real Estate (+0.7pp) and away from Health Care (-0.8pp), Other (-0.9pp).
Versus the prior quarter, TANG CAPITAL MANAGEMENT LLC opened 5 new positions, trimmed 1 and fully exited 1, a turnover rate of 15.2% of positions. The portfolio's overlap with the prior quarter was 59% of names.
The largest new positions opened in Q2 2024 were DVAX ($28.07M), JAZZ ($14.94M), TDOC ($9.78M).
Of the 1 positions fully exited versus the prior quarter, the largest were MOR ($14.52M), DCPH ($9.44M), NTLA ($5.50M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- DVAX DYNAVAX TECHNOLOGIES CORP · $28.07M
- JAZZ JAZZ PHARMACEUTICALS PLC · $14.94M
- TDOC TELADOC HEALTH INC · $9.78M
- BIIB BIOGEN INC · $8.11M
- REPL REPLIMUNE GROUP INC · $7.25M
- INSM INSMED INC · $6.70M
- BEAM BEAM THERAPEUTICS INC · $6.33M
- MRUS MERUS N V · $5.92M
Fully Exited (vs previous quarter)
- MOR MORPHOSYS AG · prev qtr: $14.52M
- DCPH DECIPHERA PHARMACEUTICALS IN · prev qtr: $9.44M
- NTLA INTELLIA THERAPEUTICS INC · prev qtr: $5.50M
- BLUE BLUEBIRD BIO INC · prev qtr: $3.20M
- EQC EQUITY COMWLTH · prev qtr: $3.12M
- MNMD MIND MEDICINE MINDMED INC · prev qtr: $2.82M
- KNTE KINNATE BIOPHARMA INC · prev qtr: $2.60M
- AMRN AMARIN CORP PLC · prev qtr: $2.23M
Insider Transactions (Form 4)
Latest TANG CAPITAL MANAGEMENT LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-10 | Buy | Boundless Bio, Inc. | 249 | $2.40 | SEC filing |
| 2026-11-06 | Buy | Boundless Bio, Inc. | 1,700 | $2.40 | SEC filing |
| 2026-11-05 | Buy | Boundless Bio, Inc. | 8,390 | $2.40 | SEC filing |
| 2026-11-04 | Buy | Boundless Bio, Inc. | 517 | $2.40 | SEC filing |
| 2026-11-03 | Buy | Boundless Bio, Inc. | 2,255 | $2.40 | SEC filing |
| 2026-10-27 | Buy | Boundless Bio, Inc. | 10,707 | $2.40 | SEC filing |
| 2026-10-26 | Buy | Boundless Bio, Inc. | 9,606 | $2.38 | SEC filing |
| 2026-10-23 | Buy | Boundless Bio, Inc. | 6,234 | $2.38 | SEC filing |
Fund Profile
Tang Capital Management is an SEC-registered 13F filer. As of Q3 2026 it reported 45 US equity positions with a combined value of $2.17B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Portfolio Structure
- 45 positions · $2.17B reported value (Q3 2026)
- Top 10 holdings = 64.3% of reported value
- Largest position: AUPH (AURINIA PHARMACEUTICALS INC) at 9.7%
- Average position size: $48.31M
Sector Tilt
- Health Care 89.7%
- Information Technology 1.5%
- (classified holdings cover 91% of value)
Quarterly Activity
- Q3 2026: 5 new, 12 added, 1 reduced, 1 exited
- 27 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.25M | $61.29M | 6.54% | Hold | |
| 2 |
|
4.85M | $52.59M | 5.61% | Add | |
| 3 |
|
4.22M | $49.70M | 5.30% | Add | |
| 4 |
|
1.33M | $33.35M | 3.56% | Hold | |
| 5 |
|
450.00K | $28.66M | 3.06% | Add | |
| 6 |
|
2.50M | $28.07M | 2.99% | New | |
| 7 |
|
27.00K | $24.45M | 2.61% | Hold | |
| 8 |
|
1.50M | $24.38M | 2.60% | Add | |
| 9 |
|
300.00K | $22.65M | 2.42% | Hold | |
| 10 |
|
700.00K | $21.41M | 2.28% | Hold | |
| 11 |
|
300.00K | $20.55M | 2.19% | Add | |
| 12 |
|
2.75M | $18.29M | 1.95% | Hold | |
| 13 |
|
1.39M | $18.12M | 1.93% | Add | |
| 14 |
|
1.23M | $17.29M | 1.84% | Add | |
| 15 |
|
316.50K | $17.09M | 1.82% | Add | |
| 16 |
|
750.00K | $16.15M | 1.72% | Add | |
| 17 |
|
921.14K | $16.06M | 1.71% | Add | |
| 18 |
|
2.78M | $15.87M | 1.69% | Add | |
| 19 |
|
400.00K | $15.40M | 1.64% | Add | |
| 20 |
|
140.00K | $14.94M | 1.59% | New | |
| 21 |
|
4.48M | $14.82M | 1.58% | Add | |
| 22 |
|
115.02K | $14.21M | 1.51% | Add | |
| 23 |
|
405.60K | $13.75M | 1.47% | Hold | |
| 24 |
|
747.62K | $12.93M | 1.38% | Add | |
| 25 |
|
2.15M | $12.17M | 1.30% | Add | |
| 26 |
|
1.62M | $11.95M | 1.27% | Hold | |
| 27 |
|
150.00K | $11.70M | 1.25% | Hold | |
| 28 |
|
625.31K | $11.67M | 1.25% | Add | |
| 29 |
|
3.75M | $10.96M | 1.17% | Add | |
| 30 |
|
2.33M | $10.88M | 1.16% | Add | |
| 31 |
|
8.22M | $9.94M | 1.06% | Add | |
| 32 |
|
1.00M | $9.78M | 1.04% | New | |
| 33 |
|
7.79M | $9.51M | 1.01% | Add | |
| 34 |
|
572.70K | $9.40M | 1.00% | Add | |
| 35 |
|
1.10M | $9.36M | 1.00% | Hold | |
| 36 |
|
720.00K | $8.71M | 0.93% | Hold | |
| 37 |
|
281.20K | $8.48M | 0.91% | Hold | |
| 38 |
|
3.06M | $8.26M | 0.88% | Hold | |
| 39 |
|
35.00K | $8.11M | 0.86% | New | |
| 40 |
|
1.60M | $7.47M | 0.80% | Hold | |
| 41 |
|
805.44K | $7.25M | 0.77% | New | |
| 42 |
|
3.10M | $7.16M | 0.76% | Hold | |
| 43 |
|
150.00K | $7.15M | 0.76% | Hold | |
| 44 |
|
264.69K | $6.85M | 0.73% | Hold | |
| 45 |
|
100.00K | $6.70M | 0.71% | New | |
| 46 |
|
1.85M | $6.47M | 0.69% | Hold | |
| 47 |
|
120.00K | $6.36M | 0.68% | Add | |
| 48 |
|
270.00K | $6.33M | 0.68% | New | |
| 49 |
|
623.33K | $6.07M | 0.65% | Add | |
| 50 |
|
100.00K | $5.92M | 0.63% | New | |
FAQ
What did TANG CAPITAL MANAGEMENT LLC buy in 2024-Q2?
In its 2024-Q2 13F filing, TANG CAPITAL MANAGEMENT LLC reported 127 equity positions worth $937.87M in aggregate; its largest disclosed positions were TARS ($61.29M), EOLS ($52.59M), KALV ($49.70M).
How large is TANG CAPITAL MANAGEMENT LLC's portfolio?
TANG CAPITAL MANAGEMENT LLC reported $937.87M of long equity holdings across 127 positions as of 2024-Q2. Top-10 holdings account for 36.9% of reported value.
What is TANG CAPITAL MANAGEMENT LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.